Array Biopharma (ARRY) Misses Q3 EPS by 4c

Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.16), $0.04 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $43 million versus the consensus estimate of $30.35 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c